Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.

Hao ChiangJinq-Chyi LeeHsiu-Chen HuangHsing HuangHui-Kang LiuCheng Huang

Published in: British journal of pharmacology (2019)

Our findings suggest the novel SGLT2 inhibitor, NGI001 has therapeutic potential to attenuate or delay the onset of diet-induced metabolic diseases and NAFLD.

Keyphrases

randomized controlled trial
oxidative stress
high fat diet induced
type diabetes
metabolic syndrome
adipose tissue
insulin resistance
skeletal muscle